Galderma, a prominent player in the dermatology sector, has received approval from the U.S. Food and Drug Administration (FDA) for its product ‘Restylane Lyft with Lidocaine.’ This innovative treatment is specifically designed for chin augmentation, aimed at enhancing the chin profile in adults over 21 experiencing mild to moderate chin retrusion.
“This FDA approval underscores our dedication to enriching our Injectable Aesthetics portfolio, the most extensive in the industry, to satisfy the varied needs of patients,” stated Bill Andriopoulos, Galderma’s Vice President of Medical Affairs, in a press release. “Expanding the applications of innovations like Restylane Lyft empowers aesthetic practitioners to better achieve their patients’ individual aesthetic aspirations with increased flexibility and precision.”
The Restylane portfolio features a comprehensive selection of hyaluronic acid (HA) injectables, including both flexible and firm gel formulations tailored for personalized aesthetic results. The 5-8 Restylane Lyft is crafted with NASHA® technology, resulting in a firmer gel that maintains minimal modification to deliver a natural appearance.
The FDA’s endorsement came after a clinical trial demonstrating the product’s safety and efficacy in enhancing chin projection, with noticeable improvements observed three months after the initial injection. Remarkably, these enhancements were sustained in the majority of participants up to 12 months later. Additionally, the study reported no unexpected or severe adverse events linked to the product, solidifying its safety profile.
